2023³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2023-09-01
±³À°ÀÏÀÚ : 2023-09-01
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ : 2023³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742
À̸ÞÀÏ : secretariat@kcnp.or.kr
±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 13 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø ¸éÁ¦/Á¤È¸¿ø 60,000¿ø/ºñȸ¿ø 70,000¿ø/ÁØȸ¿ø ¹× ±âŸ 40,000¿ø/´çÀϵî·Ïºñ Æò»ýȸ¿ø 10,000¿ø/Á¤È¸¿ø 80,000¿ø/ºñȸ¿ø 90,000¿ø/ÁØȸ¿ø ¹× ±âŸ 60,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 09:30~09:55 ¾à¹° À¯¹ß¼º ¼ö¸éÀå¾Ö ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 09:55~10:20 ¾à¹° À¯¹ß¼º ¾ß°£ Æø½Ä ÃÖ¿ø¼®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 10:20~10:40 ¾à¹° À¯¹ß¼º ±Ù°ñ°Ý°è ¼Õ»ó ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 09:30~09:55 The Impact of COVID-19 on psychiatric health in the Korean population ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 09:55~10:20 Psychotropic drug repurposing for COVID-19 °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 10:20~10:40 Antidepressant drug prescription and incidence of COVID‑19 in mental health ±è¿ìÁ¤(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 09¿ù 01ÀÏ 10:40~10:55 ()
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 10:55~11:20 °ú°Å: ÇâÁ¤½Å¼º ¾à¹°ÀÇ °³¹ß/¹ß°ßÀÇ ¿ª»ç ȲÇöÂù(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 11:20~11:45 ÇöÀç: ÇâÁ¤½Å¼º ¾à¹°ÀÇ È¿´É°ú ÇÑ°è À̺´´ë(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 11:45~12:05 ¹Ì·¡: ÇâÈÄ °³¹ß ¹æÇâ ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 10:55~11:20 5-HT ¼ö¿ëüÀÇ ºÐ·ù¿Í 5-HT1A È¿ÇöÁ¦ Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 11:20~11:45 5-HT 4, 5, 6 ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаú)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 11:45~12:05 5-HT 7 ±è³«¿µ(°è¿äº´¿ø)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 12:05~12:35 Preventing manic relapse of BPD with Aripiprazole from acute to maintenance ¼Á¤¼®(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 12:35~13:05 Exploring symptom-based approach in MDD with anxiety symptom and potential role of Aripiprazole ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 12:05~12:35 Hazard in mixed phase of bipolar patients(A.I.A./suicidality) ±è°æ¹Î(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 12:35~13:05 Importance of cognitive function & disease course in bipolar disorder Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
ÈÞ½Ä 09¿ù 01ÀÏ 13:05~13:35 ()
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 13:35~14:10 »çÀÌÅ°µ¨¸¯½º: Á¤½ÅÀÇÇп¡¼ÀÇ »ç¿ë Âù¼º È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 14:10~14:40 »çÀÌÅ°µ¨¸¯½º: Á¤½ÅÀÇÇп¡¼ÀÇ »ç¿ë ¹Ý´ë ±ÇµµÈÆ(´ëµ¿º´¿ø)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 13:35~14:10 ÀÇ·á¿ë ´ë¸¶ Àå¿ÁÁø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 14:10~14:40 Esketamine ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 14:40~15:10 ¿ì¿ïÁõÀÇ ¼¼·ÎÅä´Ñ ÀÌ·ÐÀÌ Å¸´çÇÑ °ÍÀΰ¡? Ÿ´çÇÏÁö ¾Ê´Ù. ¼ºÇü¸ð/¹®Àº¼ö(¼øõÇâÀÇ´ë/ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 15:10~15:40 ¿ì¿ïÁõÀÇ ¼¼·ÎÅä´Ñ ÀÌ·ÐÀÌ Å¸´çÇÑ °ÍÀΰ¡? Ÿ´çÇÏ´Ù. ¿ì¿µ¼·/ÀüÁø¿ë(°¡Å縯ÀÇ´ë/¿ï»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 14:40~15:00 ¼ö¸éÁ¦¸¦ º¹¿ëÇϸé Ä¡¸Å°¡ °É¸®³ª¿ä? ¾öÀ¯Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 15:00~15:20 SSRI´Â ÀÚ»ì°ú °ü·ÃÀÌ ÀÖ³ª¿ä? È«Áö¼±(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 15:20~15:40 ¾ç±Ø¼º ¿ì¿ïÁõÀÏ °æ¿ì Ç׿ì¿ïÁ¦·Î ±âºÐÀ» ¾÷ ½ÃÄÑÁÖ½Ã¸é ¾ÈµÇ³ª¿ä? ½ÉÀÎÈñ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø)
ÈÞ½Ä 09¿ù 01ÀÏ 15:40~15:50 ()
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 15:50~16:15 Á¶Çöº´¿¡ ±â´ëµÇ´Â ¾à¹° ÀÌÁß¼±(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 16:15~16:40 ±âºÐÀå¾Ö¿¡ ±â´ëµÇ´Â ¾à¹° À̹®¼ö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ÄÁº¥¼ÇȦ 16:40~17:00 Ä¡¸Å¿¡ ±â´ëµÇ´Â ¾à¹° ÀÌ°¼ö(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 15:50~16:15 General principles ÃÖÅ¿µ(´ë±¸°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 16:15~16:40 Clinical practice guidelines for autism spectrum disorders À¯ÈñÁ¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 01ÀÏ ´ëȸÀÇ½Ç 16:40~17:00 Clinical practice guidelines for the management of schizophrenia in children and adolescents ±è½Â°ï(Á¶¼±ÀÇ´ë)